Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 1:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Fat Disorder Clear all
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 10, 2026, 1:20 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

NCT02666664
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
48
States / cities
Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Sep 10, 2026, 1:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neck Fat Accumulation and Its Relationship to Cardiovascular Risk and Metabolic Syndrome

NCT02205021
View directory record Official record
Conditions
Obesity
Interventions
No intervention
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 91 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Sep 10, 2026, 1:20 PM EDT
Completed Phase 2 Interventional Results available

Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

NCT04753606
View directory record Official record
Conditions
Dyslipidemias, High Cholesterol, Hypercholesterolemia
Interventions
Obicetrapib
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
19
States / cities
Anniston, Alabama • Huntington Park, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 10, 2026, 1:20 PM EDT
Completed Not applicable Interventional

Federal Study of Adherence to Medications in the Elderly (FAME)

NCT00393419
View directory record Official record
Conditions
Medication Adherence, Hypertension, Hyperlipidemia
Interventions
Comprehensive pharmacy care program
Behavioral
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2006 · Synced Sep 10, 2026, 1:20 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

NCT06299098
View directory record Official record
Conditions
Obesity
Interventions
Trevogrumab-Part A, Trevogrumab-Part B and Part C, Garetosmab, Semaglutide, Matching Placebo-Part A, Matching Placebo-Trevogrumab, Matching Placebo-Garetosmab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,005 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
58
States / cities
Anniston, Alabama • Cullman, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 10, 2026, 1:20 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Preventing Athlete Under-fueling Through Nutrition.

NCT07136038
View directory record Official record
Conditions
Athlete, Relative Energy Deficiency in Sport, Low Energy Availability
Interventions
Low Energy Availability Screening and Nutrition Support
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 10, 2026, 1:20 PM EDT
Completed Phase 3 Interventional Results available

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

NCT01764633
View directory record Official record
Conditions
Dyslipidemia
Interventions
Evolocumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
40 Years to 85 Years
Enrollment
27,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
326
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 275 more
Source: ClinicalTrials.gov public record
Updated May 27, 2024 · Synced Sep 10, 2026, 1:20 PM EDT
Completed No phase listed Observational

A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease

NCT04721366
View directory record Official record
Conditions
Gaucher Disease
Interventions
Standard of Care
Other
Lead sponsor
Takeda
Industry
Eligibility
Up to 5 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 10, 2026, 1:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals

NCT01431690
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
warfarin, omefas, omega-3-acid ethyl esters
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 10, 2026, 1:20 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Fat Metabolism Following Chemotherapy in Breast Cancer

NCT01890824
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Texas A&M University
Other
Eligibility
30 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 10, 2026, 1:20 PM EDT
Recruiting No phase listed Observational

Fabry Disease Registry & Pregnancy Sub-registry

NCT00196742
View directory record Official record
Conditions
Fabry Disease
Interventions
Not listed
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2034
U.S. locations
92
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 10, 2026, 1:20 PM EDT
Completed Phase 2 Interventional

Dyslipidemia Study Investigating The Increase In "Good Cholesterol"

NCT00169559
View directory record Official record
Conditions
Dyslipidaemias
Interventions
GW590735, fenofibrate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2012 · Synced Sep 10, 2026, 1:20 PM EDT
Completed No phase listed Observational Results available

Lipid Metabolism in Gestational Diabetes

NCT00534105
View directory record Official record
Conditions
Gestational Diabetes, Hyperlipidemia
Interventions
Total Cholesterol, Triglyceride, HDL, LDL
Other
Lead sponsor
Baystate Medical Center
Other
Eligibility
16 Years to 40 Years · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2013 · Synced Sep 10, 2026, 1:20 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Dietary Supplementation on Body Fat Composition

NCT06296251
View directory record Official record
Conditions
Dyslipidemias, Pre-diabetes
Interventions
Placebo treatment, Plant derived phenolics
Other · Dietary Supplement
Lead sponsor
Brightseed
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 10, 2026, 1:20 PM EDT
Completed No phase listed Observational

SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function

NCT00225082
View directory record Official record
Conditions
HIV Infection
Interventions
Nucleoside analogue switch
Drug
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 4, 2010 · Synced Sep 10, 2026, 1:20 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Drug Discovery for Parkinson's With Mutations in the GBA Gene

NCT05536388
View directory record Official record
Conditions
Parkinson Disease, Gaucher Disease, Healthy, GBA Gene Mutation
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 10, 2026, 1:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood

NCT00000941
View directory record Official record
Conditions
HIV Infections
Interventions
Pravastatin sodium, Simvastatin, Atorvastatin calcium, Ritonavir, Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2002
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 10, 2026, 1:20 PM EDT
Terminated Phase 4 Interventional Results available

Lipogems Prospective Study

NCT03922490
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Lipogems Device PLUS debridement, Debridement only
Device · Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 10, 2026, 1:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise

NCT00795860
View directory record Official record
Conditions
Insulin Resistance and Type 2 Diabetes
Interventions
Weight loss - diet only, Weight loss plus exercise
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Sep 10, 2026, 1:20 PM EDT
Completed Not applicable Interventional Results available

Coordinating Pragmatic Primary Care Population Management for Obesity

NCT03998046
View directory record Official record
Conditions
Obesity, Cardiovascular Risk Factor
Interventions
Outreach Support for Weight Loss Goal Setting and Self-Weighing, Outreach Decision Support to Encourage Linkages to Intensive Community Lifestyle Interventions, Adaptive Tailoring of Information Delivery and Intensity of Primary Care Outreach Support
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Sep 10, 2026, 1:20 PM EDT
Completed Phase 2 Interventional Results available

Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

NCT04159415
View directory record Official record
Conditions
Generalized Lipodystrophy
Interventions
Placebo, Low-Dose REGN4461, High-dose REGN4461
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Bethesda, Maryland • Ann Arbor, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 10, 2026, 1:20 PM EDT
Withdrawn Not applicable Interventional

Isoleucine Addition Treatment Effects in a Controlled Diet Study

NCT07329088
View directory record Official record
Conditions
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Metabolic Syndrome (MetS), Obesity & Overweight
Interventions
L-Isoleucine, Low-isoleucine diet
Dietary Supplement · Other
Lead sponsor
Jean L. Fry
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 10, 2026, 1:20 PM EDT
Completed Not applicable Interventional

The Northwest Coalition for Primary Care Practice Support

NCT02839382
View directory record Official record
Conditions
Cardiovascular Disease, Essential Hypertension, Nicotine Dependence, Hyperlipidemia
Interventions
Coaching, Educational Outreach, Site Visits
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
Not listed
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 15, 2019 · Synced Sep 10, 2026, 1:20 PM EDT